No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NTLA240517C22500
- 1.45
- -0.60-29.27%
15min DelayClose May 8 15:59 ET
1.55High1.45Low
1.55Open2.05Pre Close110 Volume1.81K Open Interest22.50Strike Price16.36KTurnover71.09%IV3.48%PremiumMay 17, 2024Expiry Date0.50Intrinsic Value100Multiplier8DDays to Expiry0.95Time Value100Contract SizeAmericanOptions Type0.6041Delta0.1498Gamma17.69Leverage Ratio-0.0582Theta0.0031Rho10.69Eff Leverage0.0139Vega
Intraday
- 5D
- 1D
News
Why Intellia Therapeutics, Inc. (NTLA) Outpaced the Stock Market Today
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present
Express News | Intellia Therapeutics Announced The Acceptance Of An Oral Presentation From The Phase 1 Portion Of The Ongoing NTLA-2002 Phase 1/2 Study At The European Academy Of Allergy And Clinical Immunology Congress 2024
Institutional Owners May Consider Drastic Measures as Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Recent US$125m Drop Adds to Long-term Losses
Key Insights Significantly high institutional ownership implies Intellia Therapeutics' stock price is sensitive to their trading actions The top 11 shareholders own 50% of the company Recent sale
Express News | Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $29 Price Target
Intellia Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/23/2024 30.98% Wedbush → $29 Reiterates Neutral → Neutral 02/23/2024 44.53% Goldman Sachs → $32 Downgra
Comments
If you had invested $10,000 in Cathie Wood's $ARK Innovation ETF(ARKK.US$ and Warren Buffett's Berkshire Hathaway $Berkshire Hathaway-B(BRK.B.US$ at different time frames here's how much you'd have today.
When $ARKK launched in 2014
Total Returns:
$BRK.B $28.6K
$ARKK $27.4K
5 years ago
Total Returns:
$BRK.B $19.7K
$ARKK $11.7K
3 years ago
Total Returns:
$BRK.B $16.4K
$ARKK $3.3K
1 year ago
Total Returns:
$BRK.B $12.8K
$ARKK $12.4K
At the start of 2024
Total Returns:
$BR...
When $ARKK launched in 2014
Total Returns:
$BRK.B $28.6K
$ARKK $27.4K
5 years ago
Total Returns:
$BRK.B $19.7K
$ARKK $11.7K
3 years ago
Total Returns:
$BRK.B $16.4K
$ARKK $3.3K
1 year ago
Total Returns:
$BRK.B $12.8K
$ARKK $12.4K
At the start of 2024
Total Returns:
$BR...
+3
2
2
Insiders selling shares at low prices may signal expected stock weakness. The absence of insider buying and increased selling over the past year suggest the shares aren't cheap, making the company a cautious investment.
1
The first treatment based on CRISPR technology is poised to win FDA approval next month, offering hope to patients and opportunities to investors.
"A turning point in medicine"
Scientists have made significant progress in treating thousands of illnesses over the years, but finding cures for rare and deadly diseases remains a significant challenge. While treatments for inherited conditions like sickle cell...
"A turning point in medicine"
Scientists have made significant progress in treating thousands of illnesses over the years, but finding cures for rare and deadly diseases remains a significant challenge. While treatments for inherited conditions like sickle cell...
19
2
Read more